|24th September 2020||Management Inc. Opaleye||100,000||Open or private purchase||$16.87||$1,687,000.00|
|24th September 2020||Management Inc. Opaleye||200,000||Open or private purchase||$16.87||$3,374,000.00|
|22nd September 2020||Blaine Davis||1,481||Open or private purchase||$16.91||$25,037.79|
|18th September 2020||John Gordon Freund||400,000||Open or private sale||$12.00||$4,800,000.00|
|14th September 2020||Randall Marshall||474||Open or private sale||$20.00||$9,480.00|
|14th September 2020||Randall Marshall||2,080||Open or private sale||$19.26||$40,060.80|
|11th September 2020||John Gordon Freund||500,000||Open or private sale||$10.00||$5,000,000.00|
|10th September 2020||Randall Marshall||239||Open or private sale||$18.00||$4,302.00|
|9th September 2020||Randall Marshall||5,309||Open or private sale||$18.10||$96,092.90|
|9th September 2020||Management Inc. Opaleye||45,000||Open or private purchase||$3.47||$156,100.50|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001.